olaparib
olaparib 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Epithelial Ovarian Cancer。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
24 项
全球在招研究
5 项
已进入 III/IV 期
20 个
开展国家和地区
有
中国境内设点
药品与企业信息
研发企业
- AGO Research GmbH
- Beijing Tide Pharmaceutical Co., Ltd
- National Cancer Centre, Singapore
- Prof. Wolfgang Janni
- CCTU- Cancer Theme
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Exelixis
- Wen-Ming Cao
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
中国、Singapore、德国、英国、美国、South Korea、西班牙、法国、日本、Puerto Rico、Argentina、澳大利亚
正在招募患者的 olaparib 研究
An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors
I 期 / II 期招募中中国NCT07371663Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma
II 期招募中SingaporeNCT06160843A Randomized Secondary Adjuvant Treatment Intervention Study Comparing Trastuzumab-Deruxtecan to SOC Therapy in eBC Patients With Molecular Relapse
III 期招募中德国NCT06643585WIRE - Novel Treatments in Renal Cell Cancer
II 期招募中英国NCT03741426PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
II 期招募中美国NCT06245889A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors
I 期招募中美国NCT05932862Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
IV 期招募中中国NCT07695259I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
II 期招募中美国NCT01042379Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer
I 期 / II 期招募中South KoreaNCT04592211Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
I 期招募中英国NCT06976892Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
II 期招募中美国NCT04038502Evaluating the Efficacy and Safety of Fulvestrant Plus DNA Damage Repair Inhibitors After a CDK4/6 Inhibitor
II 期招募中South KoreaNCT05536128PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
II 期招募中英国NCT03740893Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer
I 期招募中美国NCT07652242Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
I 期 / II 期招募中西班牙NCT06607692WoO: Window of Opportunity Trial of Olaparib and Durvalumab in Histologically Proven EOC
II 期招募中德国NCT04644289Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endometrial Cancer
III 期招募中法国NCT06712472Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
I 期招募中美国NCT05900895Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
I 期招募中美国NCT07382544Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment
II 期招募中法国NCT02029001Telmisartan in Prostate Cancer
I 期招募中美国NCT06168487Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
III 期招募中美国日本Puerto RicoNCT06580314Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
III 期招募中美国Argentina澳大利亚奥地利NCT03486873A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
I 期招募中South KoreaNCT07069335
中国患者怎么争取用上这款药
这款药已经有研究在中国境内设点，可以先带完整病历去对应医院咨询入组；同时也可以并行了解下面几条途径，多一条备选。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。